Clinical Trial Update: EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical Trial Update on an ongoing Phase 1/2 study of allogeneic NK cells (EBNK-001) with low-dose interleukin-15, with or without pembrolizumab, in patients w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Esophageal Cancer
• Glioblastoma
• Lung Cancer
• Melanoma
• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• EBNK-001
• Interleukin-15 (interleukin-15)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Essen Biotech | Conditions: Cancer, Sarcoma | Phase 1, Phase 2 | Status: RECRUITING